VIEWS: 17 PAGES: 33 CATEGORY: Market and Industry Reports POSTED ON: 11/10/2011
Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “Karus Therapeutics Ltd - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- Karus Therapeutics Ltd - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Karus Therapeutics Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Karus Therapeutics Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Karus Therapeutics Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Karus Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Karus Therapeutics Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Karus Therapeutics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opport
Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011 Reference Code: GMDHC1073CDB Publication Date: MAR 2011 Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011 GMDHC1073CDB / Published MAR 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Karus Therapeutics Ltd – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 4 List of Figures 4 Karus Therapeutics Ltd Snapshot 5 Karus Therapeutics Ltd Overview 5 Key Information 5 Key Facts 5 Karus Therapeutics Ltd – Research and Development Overview 6 Key Therapeutic Areas 6 Karus Therapeutics Ltd – Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products – Monotherapy 9 Karus Therapeutics Ltd – Pipeline Products Glance 10 Karus Therapeutics Ltd–Early Stage Pipeline Products 10 Pre-Clinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 Karus Therapeutics Ltd – Drug Profiles 12 KAR1141 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 KAR2581 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 KAR3166 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 KAR1139 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 KAR3000 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Karus Therapeutics Ltd – Pipeline Analysis 17 Karus Therapeutics Ltd – Pipeline Products by Therapeutic Class 17 Karus Therapeutics Ltd - Pipeline Products By Target 18 Karus Therapeutics Ltd – Pipeline Products by Route of Administration 19 Karus Therapeutics Ltd – Pipeline Products by Molecule Type 20 Karus Therapeutics Ltd – Locations And Subsidiaries 21 Head Office 21 Recent Developments 22 Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6 22 Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011 GMDHC1073CDB / Published MAR 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Karus Therapeutics Ltd – Product Pipeline Review Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6 23 Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6 24 Sep 23, 2009: Karus Therapeutics And Queen Mary, University Of London Announce PI3 Kinase Collaboration 25 Financial Deals Landscape 27 Karus Therapeutics Ltd, Deals Summary, 2004 to 2011 27 Karus Therapeutics Ltd Detailed Deal Summary 28 Venture Financing 28 Karus Therapeutics Secures $1.47 Million In Venture Financing 28 Karus Therapeutics Secures $1.65 Million In Venture Financing 30 Karus Therapeutics Enters Into Co-Development Agreement With Queen Mary 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 33 Contact Us 33 Disclaimer 33 Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011
Pages to are hidden for
"Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011"Please download to view full document